Unknown PHASE1 INTERVENTIONAL NCT00409201

Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia

Phase 1 Study of Reboxetine Adjuvant Therapy and Cognitive and Behavioral Measures

Sponsor: Abarbanel Mental Health Center

Interventions reboxetine adjuvant therapy

Updated 4 times since 2017 Last updated: Dec 7, 2006 Started: Mar 31, 2006 Completion: Nov 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Schizophrenia, this trial is ongoing. The trial is conducted by Abarbanel Mental Health Center and has accumulated 4 data snapshots since 2006. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE1

First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abarbanel Mental Health Center

Data source: Abarbanel Mental Health Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bat Yam, Israel